中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2008年
5期
734-735
,共2页
疱疹%生殖器%T淋巴细胞%辅助诱导%伐昔洛韦%乌体林斯
皰疹%生殖器%T淋巴細胞%輔助誘導%伐昔洛韋%烏體林斯
포진%생식기%T림파세포%보조유도%벌석락위%오체림사
Herpes%Genitalis%T-lymphocytos%helper-inducer%Valaciclovir%Mycobacterium phle
目的 探讨两种方法治疗复发性生殖器疱疹(RGH)患者疗效及对T细胞亚群的影响.方法 64例RGH患者随机分为联合治疗组32例、对照组32例,对照组口服伐昔洛韦片治疗,联合治疗组除口服伐昔洛韦片外,还接受乌体林斯注射液治疗,观察两组的治疗效果,并检测治疗前后T细胞亚群情况.结果 联合治疗组治疗后RGH复发频率[(1.01±0.79)次/年]较对照组[(2.53±0.93)次/年]明显下降(P<0.01);联合治疗组治疗后CD+4T细胞数[(40.38±6.85)%]及CD+4/CD+8比值(1.59±0.50)均较对照组[(36.28±6.76)%,(1.28±0.49)%]明显升高(P<0.05),CD+8细胞数[(26.32±6.05)%]较对照组[(29.73±5.49)%]明显下降(P<0.05).结论 RGH患者存在细胞免疫功能异常,伐昔洛韦联合乌体林斯治疗RGH,可以增强细胞免疫,提高治疗效果.
目的 探討兩種方法治療複髮性生殖器皰疹(RGH)患者療效及對T細胞亞群的影響.方法 64例RGH患者隨機分為聯閤治療組32例、對照組32例,對照組口服伐昔洛韋片治療,聯閤治療組除口服伐昔洛韋片外,還接受烏體林斯註射液治療,觀察兩組的治療效果,併檢測治療前後T細胞亞群情況.結果 聯閤治療組治療後RGH複髮頻率[(1.01±0.79)次/年]較對照組[(2.53±0.93)次/年]明顯下降(P<0.01);聯閤治療組治療後CD+4T細胞數[(40.38±6.85)%]及CD+4/CD+8比值(1.59±0.50)均較對照組[(36.28±6.76)%,(1.28±0.49)%]明顯升高(P<0.05),CD+8細胞數[(26.32±6.05)%]較對照組[(29.73±5.49)%]明顯下降(P<0.05).結論 RGH患者存在細胞免疫功能異常,伐昔洛韋聯閤烏體林斯治療RGH,可以增彊細胞免疫,提高治療效果.
목적 탐토량충방법치료복발성생식기포진(RGH)환자료효급대T세포아군적영향.방법 64례RGH환자수궤분위연합치료조32례、대조조32례,대조조구복벌석락위편치료,연합치료조제구복벌석락위편외,환접수오체림사주사액치료,관찰량조적치료효과,병검측치료전후T세포아군정황.결과 연합치료조치료후RGH복발빈솔[(1.01±0.79)차/년]교대조조[(2.53±0.93)차/년]명현하강(P<0.01);연합치료조치료후CD+4T세포수[(40.38±6.85)%]급CD+4/CD+8비치(1.59±0.50)균교대조조[(36.28±6.76)%,(1.28±0.49)%]명현승고(P<0.05),CD+8세포수[(26.32±6.05)%]교대조조[(29.73±5.49)%]명현하강(P<0.05).결론 RGH환자존재세포면역공능이상,벌석락위연합오체림사치료RGH,가이증강세포면역,제고치료효과.
Objective To explore the influence of the treatment and T-cell subsets in patients with recurrent genital herpes (RGH) by two treatment methods. Methods 64 cases of RGH patients were randomly divided int0 2 groups: 32 patients in the unite treatment group, the control group of 32 patients. Control group oral valaciclovir. The unite treatment group of oral valaciclovir tablets, in addition, also accepted mycobacterium phle injection treatment. All the patients before and after treatment were analyzed by flow cytometry using T-cell subsets. Results In the unite treatment group after treatment RGH relapse frequency [(1.01±0.79)] than that of the control group [(2.53±0.93)] was significantly decreased (P<0.001). In the unite treatment group after treatment CD+4 T cells and CDCD+4/CDCD+8 ratio than the control group were significantly increased (P<0.05), CD+8 cells compared with the control group was significantly decreased (P<0.05). Conclusion The cellular immunity is abnormal in RGH patients and it plays an important role in pathogenesis of RGH. Mycobacterium phle may enhance cellular immunity of the patients and these patients treated with it showed some better effects.
